New hepatitis b drug shows promise in large trial
NCT ID NCT07203118
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new medication called hepenofovir fumarate (HTS) for people with chronic hepatitis B, a long-term liver infection. About 1,444 adults aged 18-65 who have not been treated before (or stopped treatment at least 6 months ago) will take one of three doses of HTS or the standard drug TAF daily. The goal is to see which dose works best and is safest, with the hope of offering a new treatment option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
hepenofovir fumarate (HTS)
What this could lead to
If successful, this could provide a new once-daily pill option to control chronic hepatitis B, potentially with better safety or efficacy than current treatments.
What could go wrong
This is an early-to-mid stage trial, so the drug may not prove more effective or safer than existing therapy. Side effects are still being evaluated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Hospital of Jilin University
Jilin City, changchun, China